The shares of Pharma Company Laus Labs Limited showed up to 7.5 percent a day on July 28. Along with this, the stock created a 52 -week fresh high 901 rupees on BSE. The stock later rose by 6 percent to close at Rs 888.70. The company had told the stock markets a day earlier that the Andhra Pradesh government had allotted 531.77 acres of land in IP Rambilli Phase II in Ankapalli district.
This land has been received by the company to create a manufacturing units for pharma products to create a Lerus Pharma Zone (LPZ). This project is expected to invest Rs 5630 crore in 3 phases in 8 years and 6350 people will get employment. Due to this development, the stock procurement increased.
After the June quarter results, brokerage has increased the target price for Laus Labs share but still these are up to 37.5 percent less than the current price. Brokerage Goldman Sachs, Jefferies and Kotak Institutional Equities are negative for the share of Laus Labs.
Goldman Sachs has rated the ‘SAIL’ for the share. The target price has been increased to Rs 675 per share. This is 24 percent less than the current price of the stock.
In the April-June 2025 quarter, the company’s sales increased by 31 percent and Ebitda 124 percent. This is more than the estimate of brokerage. Ebitda margin 1002 basis points rose to 24.3%. The management of Laus Labs is expected to be more better in FY 2026.
Jeffers has rated the rating for Laurus Labs shares. The target price has been increased from ₹ 480 to ₹ 590 per share. Brokerage says the company’s earnings have been better than the June quarter estimate.
Kotak Institutional Equities have given a target price of ₹ 555 per share with ‘SAIL’ rating for stock. Earlier it was ₹ 475 per share. The new target is 37.5 percent lower than the current price of the share.
The market cap of Laus Labs is Rs 47900 crore. The face value of the stock is Rs 2. In the last one year, share investors’ money has almost doubled.